Cemiplimab Interactions
There are 593 drugs known to interact with cemiplimab, along with 8 disease interactions. Of the total drug interactions, 3 are major, and 590 are moderate.
- View all 593 medications that may interact with cemiplimab
- View cemiplimab disease interactions (8)
Most frequently checked interactions
View interaction reports for cemiplimab and the medicines listed below.
- Acetylsalicylic Acid (aspirin)
- Activated Charcoal (charcoal)
- Actonel (risedronate)
- Advair Diskus (fluticasone / salmeterol)
- Alcohol (contained in alcoholic beverages) (ethanol)
- Aspirin Low Strength (aspirin)
- Centrum Silver (multivitamin with minerals)
- Co-trimoxazole (sulfamethoxazole / trimethoprim)
- Coenzyme Q10 (ubiquinone)
- Copper (copper gluconate)
- Cymbalta (duloxetine)
- Denorex Therapeutic (coal tar/menthol topical)
- Dexilant (dexlansoprazole)
- Dextrose (glucose)
- Diflucan (fluconazole)
- Diltiazem Hydrochloride SR (diltiazem)
- Dymista (azelastine / fluticasone nasal)
- Eliquis (apixaban)
- Ethyl Alcohol (ethanol)
- Fentanyl Transdermal System (fentanyl)
- Fish Oil (omega-3 polyunsaturated fatty acids)
- Flovent HFA (fluticasone)
- Glycerol (glycerin)
- Heparin Sodium (heparin)
- Metoprolol Succinate ER (metoprolol)
- Paracetamol (acetaminophen)
- Quercetin (bioflavonoids)
- Vitamin B12 (cyanocobalamin)
- Vitamin C (ascorbic acid)
- Vitamin D3 (cholecalciferol)
Cemiplimab disease interactions
There are 8 disease interactions with cemiplimab which include:
- immune system disorder
- colitis
- hepatic impairment
- nephritis/renal dysfunction
- previous chest radiation
- HSCT
- myasthenia gravis
- organ transplant
Report options
More about cemiplimab
- cemiplimab consumer information
- Compare alternatives
- Reviews (10)
- Side effects
- Dosage information
- During pregnancy
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Libtayo
Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell ...
Erbitux
Erbitux (cetuximab) is used to treat cancers of the colon and rectum. Learn about side effects ...
Blenoxane
Blenoxane is used for hodgkin's lymphoma, non-hodgkin's lymphoma, squamous cell carcinoma ...
Unloxcyt
Unloxcyt (cosibelimab-ipdl) is an anti-PD-1 treatment for metastatic or advanced cutaneous squamous ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
